Cell Cycle

The cell cycle consists of a regulatory network of proteins that controls the order and timing of cellular proliferation events. It is divided into four stages, G1-S-G2-M. The G1 and G2 stages stands for 'GAP 1' and 'GAP 2' respectively. The S stage stands for 'Synthesis' and is the stage when DNA replication occurs. The M stage stands for 'mitosis', and is when nuclear and cytoplasmic division occurs, halving the genome.

Cell Cycle Products Targets

Products for Cell Cycle - Page 9

Cat.No. Product Name Information/Activity
BCC2241 Pifithrin-α (PFTα) Pifithrin-α hydrobromide is a p53 inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an aryl hydrocarbon receptor (AhR) agonist.
BCC2407 Cyclic Pifithrin-α hydrobromide Pifithrin-β hydrobromide (PFT β hydrobromide) is a potent p53 inhibitor with an IC50 of 23 μM.
BCC2412 Pifithrin-μ Pifithrin-μ is an inhibitor of p53 and HSP70, with antitumor and neuroprotective activity.
BCC2408 HLI 373 Hdm2 inhibitor; activates p53-dependent transcription
BCC2410 NSC 146109 hydrochloride NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and could be of value in treating breast cancer. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes[1].
BCC2242 NSC 319726 NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.
BCC2255 NSC 66811 MDM2 inhibitor. Disrupts MDM2-p53 interaction
BCC2238 RITA (NSC 652287) RITA is an inhibitor of p53-HDM-2 interaction, binds to p53dN, with a Kd of 1.5 nM, and also induces DNA-DNA cross-links.
BCC2416 SJ 172550 SJ-172550 is a small molecule inhibitor of MDMX; competes for the wild type p53 peptide binding to MDMX with an EC50 of 5 μM.
BCC2239 Tenovin-1 Tenovin-1 is an inhibitor of sirtuin 1 and sirtuin 2, an activator of p53 and may have potential in the management of cancer.